Oncology is moving toward a future in which treatments are genetically matched to patients’ tumors. But we won’t get there without generating a lot more awareness about molecular diagnostics, says Caris’ commercial chief.
Opdivo’s commercial potential will likely take a hit in the wake of new Keytruda data, but the impact may depend on the ability of BMS to market the message that its I-O/I-O combo allows patients to delay chemo.
Has DTC in the oncology space kept up with science?
As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.
As CAR-Ts go from candidates to brands, what’s the marketing strategy?
Heathline Media’s Brendan McHenry discusses complementary health and financial wellness as pillars of the company’s Whole Person Health Initiative.
Rewriting the traditional launch playbook
For the growing number of HCPs who are digital natives, digital channels provide a more convenient and flexible way to engage in launches moving forward.
Debunking telemedicine myths beyond the pandemic
The reality is telemedicine is here to stay.
Partner Content, Podcasts
MM+M podcast with DeepIntent
Surveying patients for a new research report, DeepIntent found that nearly three-quarters of patients believe more lives can be saved if people were better informed about their treatment options — and that many patients don’t feel informed.
Want to read more?
Please login or register first to view this content.